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Abstract Objectives Infantile hemangioma (IH) is the most
common childhood benign tumour. A recent phase II/III
study has demonstrated the success of propranolol for in-
volution of infantile hemangioma as well as a better efficacy
and safety when indirectly compared with corticosteroids.
The purpose of this study was to estimate the cost-utility of
propranolol (Hemangiol), a new medicinal product and the
first to be authorized for this specific paediatric indication,
versus corticosteroids in the treatment of proliferating infan-
tile hemangioma requiring systemic therapy.
Methods A life-time mixed decision tree and Markov model
was developed to describe the pathway of infants with infan-
tile hemangioma and to assess costs and outcomes in terms
of Quality Adjusted Life Years (QALYs) from the perspec-
tive of the Italian National Health Service. Clinical inputs
were derived from the MA holder’s pivotal trial and lit-
erature review, and were validated by disease key opinion
leaders in Italy. The economic evaluation considered direct
medical costs associated with infantile hemangioma, derived
from public sources. Atopic dermatitis utilities were used as
a proxy for infantile hemangioma. Probabilistic sensitivity
analysis was performed to investigate model parameter vari-
abilities.
Results The cumulative costs were €2,399.32 and €1,859.
68, while cumulative QALYs were 19.11 and 18.95, respec-
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tively for propranolol and corticosteroids (Prednisolone-
Deltacortene), corresponding to an incremental cost-utility
ratio of €3,372.75 per QALY. Probabilistic sensitivity anal-
ysis showed that 94.60% of the 1,000 iterations fall within
an a priori €30,000/QALY cost-effectiveness threshold.
Conclusions Propranolol oral solution for the treatment of
proliferating infantile hemangioma requiring systemic ther-
apy can be considered cost-effective compared to corticos-
teroids from the Italian National Health Service (NHS) per-
spective at a threshold fixed at €30,000/QALY.
Key points for decision makers
• Infantile hemangioma is the most common benign
childhood tumour;
• In 12% of cases, infantile hemangioma requires a sys-
temic therapy:
◦ Life- or function-threatening hemangioma
◦ Ulcerated hemangioma with pain and/or lack of re-
sponse to simple wound care measures
◦ Hemangioma with a risk of permanent scars or dis-
figurement;
• Propranolol has demonstrated its efficacy and safety in
this infantile population;
• Propranolol is the treatment of choice as a first line ther-
apy in IH;
• Propranolol is more effective and better tolerated than
corticosteroids [1–5];
• Propanolol oral solution especially developed for paedi-
atric use through a Paediatric Investigation Plan (PIP),
is the first drug authorized for the treatment of IH, with
a Paediatric Use Marketing Authorization (PUMA);
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• Propranolol for the treatment of proliferating IH requir-
ing systemic therapy can be considered cost-effective
compared to corticosteroids from the Italian National
Health Service perspective.
1 Introduction
Infantile Hemangioma (IH) is a benign vascular tumour
characterized by endothelial cell proliferation of blood ves-
sels in the skin and/or visceral organs. It affects 3% to 10%
of all infants under one year of age, resulting in one of the
most common benign tumours of infancy [6]. This kind of
tumour originates lesions composed of microscopic blood
vessels that can be very close to the skin surface, causing
the strawberry red colour and the uneven texture. The blood
vessels also can be deep in the fat of the skin appearing as a
smooth bump under the skin surface [7, 8].
IH shows a peculiar evolution with rapid growth within
early infancy, followed by slow involution over the next sev-
eral years. Indeed, IH appears at birth or within the first few
weeks of life (2–4 weeks after birth) and generally grow over
the first 6 months of life (proliferation phase), followed by
plateau phase and gradual spontaneous involution within 5
to 7 years (involution phase) [8–10].
Several classifications of IH exist. In the past, IHs were
classified based on the depth of involved soft tissue in su-
perficial, deep or mixed. Recently, the Guidelines from the
Italian Society for the Study of Vascular Anomaliesbase
the classification of IH on the distribution and tumours are
grouped in focal, multifocal, segmental and eruptive [11].
Most of IHs are small and restricted in area, resulting in
no need for treatment since the lesions regress over years
without leading to functional impairments or leaving signif-
icant residuals. However, about 12% of IHs are more com-
plex and can be associated with severe complications for the
patients, therefore requiring treatment [12]. Several compli-
cations can derive from growth of IH, ulceration, bleeding,
visual defects, airway obstruction, congestive heart failure
and, rarely, death [13].
In the absence of registered treatment options, oral corti-
costeroids were considered first-line therapy of IHs for long
time, as recommended in national guidelines. However, data
show that corticosteroids only inhibit the tumour growth
rather than reduce its size [8, 14]. Moreover, the use of cor-
ticosteroids is associated with an unsatisfactory safety pro-
file, causing various and sometimes serious side effects such
as interruption of growth, hypertension, glaucoma, obesity,
‘moon face’ [15].
In 2008, Léauté-Labrèze and colleagues, experts prac-
ticing at Children’s Hospital in Bordeaux, published their
observation that propranolol, a non-selective beta-blocker,
had beneficial effects on IH involution. Indeed, they demon-
strated that oral propranolol produces not only stabilization
but a regression of proliferating hemangioma, without se-
vere side effects [16]. Other studies also demonstrated that
oral propranolol provides greater efficacy and higher safety
profile than corticosteroids in the treatment of IH [1]. How-
ever, the off-label use of the drug resulted in high risks of
inappropriate dose in infants, since the therapy was adapted
from adult dosage to paediatric populations without an ap-
propriate formulation for young children [2, 3]. Therefore,
in order to fill the unmet need in the management of the in-
fants affected by IH, an oral paediatric-specific formulation
of propranolol for the treatment of proliferating IH requiring
systemic therapy was developed and its efficacy and safety
at the most effective dosage demonstrated in a phase 2/3
study leading to a market authorization granted by European
Medicines Agency (EMA) [17].
The purpose of the present study was to assess the cost-
utility of propranolol (Hemangiol), paediatric use formu-
lation (3.75 mg/mL, oral solution), versus corticosteroids
(Prednisolone-Deltacortene) (5.00 mg, tablets) in the treat-
ment of infants with proliferating IH requiring systemic
treatment from the Italian NHS perspective.
2 Methods
2.1 Study design
A cost-utility analysis on two treatment strategies [systemic
therapy with propranolol oral solution versus systemic ther-
apy with corticosteroids] was conducted to assess the costs
and clinical benefits of propranolol in comparison to corti-
costeroids in the treatment of proliferating IH in Italy. The
cost-utility results were reported in terms of incremental
cost per QALY gained and expressed by Incremental Cost-
Utility Ratio (ICUR).
The results of economic evaluation were expressed in
terms of resource consumption and in terms of clinical effec-
tiveness measured by QALYs gained. Therefore the primary
outcome was the incremental total costs per QALY that ex-
presses the additional costs implied by adoption of the in-
novative treatment with propranolol oral solution to gain an
additional life year in perfect health. Then, the primary out-
come of analysis was expressed in quantitative terms by in-
cremental cost-utility ratio, exploring the cost-utility of pro-
pranolol oral solution in the treatment of proliferating IH
requiring systemic treatment.
The Italian National Health Service perspective was
adopted to evaluate the resource consumption with a life-
time (30 years) time-horizon, by applying a 3.00% dis-
count rate to both costs and health benefits as indicated in
Italian guidelines for Economic Evaluation of Health Pro-
grams [18].
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Fig. 1 Structure of decision tree and Markov model of cost-utility analysis
Probabilistic sensitivity analysis was performed to assess
the uncertainty around the ICUR.
The probabilistic sensitivity analysis was performed by
varying the model input, modelling the transition probability
as beta-distributions and the costs as gamma-distributions
for 1,000 iterations.
2.2 Model overview
A mixed decision tree—Markov model was developed in or-
der to describe the pathway of infants with proliferating IH
requiring systemic treatment. The model, shown in Fig. 1,
is divided in 3 macro-phases representing the evolution of
IH and the current practice in management of the affected
infants: “Active treatment phase”, “Stabilization and invo-
lution phase” and “Post-involution phase”. The Active treat-
ment phase comprises three health states: “Success”, defined
as a complete or nearly complete resolution of lesions; “No
Success”, defined as lack of complete or nearly complete
resolution of lesions; “Drop-out”, defined as the discontinu-
ation of trial treatment. The other two phases comprise two
health states: “Success” and “No success”.
The first phase represents the proliferation period of he-
mangioma, in which it is necessary to initiate the active ther-
apy (propranolol or corticosteroids). In this phase the transi-
tion from “No Success” to “Success” health state depends on
the clinical efficacy of the pharmaceutical therapy (Table 1).
Following the active treatment period, the second phase
of the model focuses on spontaneous involution of IH and
lasts from the age of 1 year until the age of 6 year, as demon-
strated in a retrospective analysis [8]. During the involution
phase the model utilizes the transition from “No Success” to
“Success” health state which can occur through spontaneous
involution of the hemangioma or through active intervention
of sequelaes (e.g. surgical resection, laser therapy, or a com-
bination of both). Worsening in the involution phase (transi-
tion from “Success” to “No Success”) is not to be expected,
due to clinical experience.
In the “Post-involution phase” the residual lesions do not
resolve spontaneously anymore because the involution pro-
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Table 1 Clinical outcomes defining the transition probability between health states during the “Active treatment phase: 6 months (age 3–9
months)”
Success rate* Drop-out rate** Rebound rate*** Ulceration events rate**** Adverse events rate*****
Propranolol19 60.40% 13.70% 11.40% 6.00% 6.00%
Corticosteroids1,3,15,20 44.10% 13.70% 36.00% 26.00% 35.00%
*Success rate = complete or nearly complete resolution of IH
**Drop-out rate= discontinuation of trial treatment. For corticosteroids is assumed the same of propranolol treatment
***Rebound rate = reintroduction of systemic hemangioma treatment after propranolol/corticosteroids treatment
****Ulceration event rate = complications due to proliferation of hemangioma
*****Adverse events rate = complications related to pharmaceutical therapy
cess is complete. From this time onward, resolution can only
occur through active intervention, and it is further assumed
that any active treatment will lead to a complete success.
The model was developed with Microsoft Excel.
2.3 Clinical data source
The model was populated with clinical efficacy data which
define the transition probability from one health state to an-
other. The clinical efficacy data related to propranolol treat-
ment were obtained from the pivotal head-to-head trial ver-
sus placebo published in 2015 in the NEJM [19]. The clin-
ical effectiveness data related to corticosteroids treatment
were derived from systematic literature review, more specif-
ically from two meta-analyses of observational studies con-
ducted by Izadpanah et al. and by Bennet et al. [1, 3, 15, 20].
The main clinical outcomes taken into account in the
model were success rate (i.e. the complete or nearly com-
plete resolution of IH), drop-out rate (i.e. the discontinuation
of trial treatment) and rebound rate (i.e. the reintroduction of
systemic hemangioma treatment after therapy with propra-
nolol or corticosteroids). Furthermore, the model incorpo-
rates the ulceration (i.e. complications due to proliferation of
hemangioma) and adverse events (i.e. complications related
to pharmaceutical therapy) related to the different therapeu-
tic approaches. Table 1 indicates all main clinical outcomes
that define the transition probability between health states.
Moreover, the model assumes that during the “Stabiliza-
tion and involution phase” in 50% of patients, for whom
pharmacological treatment was not completely effective, he-
mangioma spontaneously involutes [21, 22]. Whereas in
20% of patients an active intervention, like laser treatment,
surgery or a combination of both, is necessary to remove
residual hemangioma [22]. Table 2 shows treatment modal-
ity distribution for residual lesions in “Stabilization and in-
volution phase” and in “Post-involution phase”. In the “Post-
involution phase” the model assumes that residual lesions
were presented in 69% of patients [23].
Table 2 Treatment modality distribution for residual lesions in “Invo-




Combination of two treatment* 12.50%
*Combination = Surgery resection + Laser therapy
2.4 Utilities
Since no utility value was estimated for the condition of IH
(corresponding to the health state “No Success”) or is avail-
able in literature, the utility estimate for atopic dermatitis
was selected as a proxy for IH utilities. The used utility data
were extrapolated from a work done by Monti at al. that es-
timated the utility in an Italian sample of children (aged be-
tween 1–12 years) affected by atopic dermatitis using the
Infants Dermatitis Quality of Life Index (IDQoL) and the
Children’s Dermatology Life Quality Index (CDLQI).1 In
accordance with results of this study, the level of utility as-
sociated with a patient affected by IH, using atopic dermati-
tis as proxy, was set equal to 0.76 (adjusted on scale from 0
to 1) during the proliferative phase and modelled according
to the evolution of the disease [24].
Moreover, in the estimation of the quality of life, the de-
crease of utility due to the use of corticosteroids was taken
into account. Indeed, the administration of these drugs has a
greater impact on utility perceived by patients and their fam-
ilies than the administration of propranolol, due to the higher
incidence of toxicity and side effects of corticosteroids [1].
The decrease of utility was quantified equal to 3%, in accor-
dance with a study conducted in UK that assessed the Utility
1In particular, the mothers filled the IDQoL questionnaire for children
age 1–4 years. While, children age 5–12 years completed the CDLQI
questionnaire by themselves and in some cases with the help of their
mother.
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in patients with atopic dermatitis treated with corticosteroids
compared to a less toxic treatment [25].
2.5 Resource use and costs
The evaluation of resource consumption was conducted on
the basis of the clinical pathway of infants, modelled in the
decision model and based on interviews done with key opin-
ion leaders experienced in the treatment of IH. The inter-
views were focused on dosage and length of pharmaceutical
therapy, treatment setting (outpatient, day-hospital or inpa-
tient care) and the frequency and type of monitoring visits
in follow-up plan.
The economic evaluation considered only direct medi-
cal costs associated with drug acquisition, hospital admis-
sions and outpatient visits. The direct non-medical costs
such as travelling; waiting periods and indirect costs were
not included in the analysis according to the Italian National
Health Service perspective adopted.
The estimation of the pharmaceutical costs was per-
formed on base of ex-factory price of the respective drugs, as
this represents the maximum cost for the public structures.
The cost of propranolol was fixed at €180.50 (3.75 mg/mL,
oral solution for paediatric use, bottle of 120 mL. The cost
of corticosteroids was obtained from “Compendio Farma-
ceutico Telematico-Farmadati 2013” equivalent to €1.04
(5.00 mg, tablets). While the dosage and the duration of ther-
apy were determined according to the data collected in the
interviews with expert opinion.
The resource consumption for hospitalization was esti-
mated following the DRG-based reimbursement system, us-
ing version 24 of DRG-Grouper and the national tariffs es-
tablished by Ministerial Decree of 18th October, 2012 [26].
The hospital admission for the first administration of the
drug, necessary for both evaluated clinical pathways, was
coded by DRG 284 “Minor skin disorders without compli-
cations” to which a tariff equal to €153.00 in day hospi-
tal setting is associated [26]. The first administration of the
therapy was considered in day hospital setting also for cor-
ticosteroids according to the opinion of Clinical Experts of
three Reference National Centres of this pathology, based in
northern, central and southern Italy, considering the distinc-
tive features of patient under one year of age and the well-
known adverse event related to the corticosteroids treatment.
The hospitalization for the surgical resection of residual le-
sions was coded by DRG 120 “Other acts on cardiovascular
system” to which a tariff equal to €1,898.00 in day hospi-
tal setting is associated [24]. While the estimate of the cost
related to laser therapy to remove residual lesions was per-
formed according to DRG 270 “Other acts on skin” and to
the number of sessions necessary to remove the lesions (re-
quiring 3 sessions on average). The total cost associated with
laser therapy resulted in €3,297.00 [24].
The resources associated with outpatient visits for the
follow-up of the pharmaceutical treatment were estimated
on basis of National Outpatient Tariffs established by Min-
isterial Decree of 18th October, 2012 [26]. In particular, the
follow-up plan for the patients treated with propranolol in-
volves a dermatological visit scheduled monthly, to which
a tariff equal to €20.66 is associated. While for the patients
treated with corticosteroids the follow-up plan is more inten-
sive, consisting of a dermatological and a general outpatient
visit conducted monthly, to which a tariff equal to €20.66
for both visits is associated.
The model also included the representation of ulceration
and adverse events resulting from pharmaceutical therapies
(the ulceration is not generally related to the therapy but it
is a potential complication of IH most frequently during the
3–4th month, potentially requiring laser and weekly outpa-
tient visits to prevent infection). The costs associated with
treatment of ulceration were estimated with reference to the
current clinical practice, that involves two sessions of laser
treatment performed in day-hospital setting and coded by
DRG 270 “Other skin procedure without complications”,
to which a tariff of €1,099.00 is associated. In succession,
four dermatological outpatient visits are performed to mon-
itor evolution of the ulceration. On the base of this informa-
tion, the total cost of managing ulceration was estimated at
€2,280.64.
The costs associated with adverse events related to pro-
pranolol treatment were quantified assuming that a hospital
admission in day hospital setting is necessary to treat the
complication. This hospitalization was coded by DRG 284
“Minor skin disorders without complications,” to which a
tariff equal to €153.00 is associated. For the management
of complications resulting from the use of corticosteroids
the costs were estimated by the average of costs related to
the most frequent adverse events, like: hypertension caused
by corticosteroids, interruption of growth, glaucoma, obe-
sity, ‘moon face’ [15]. This estimate was conducted tak-
ing into consideration additional costs for pharmaceutical
treatments, hospital admissions and outpatient visits, and
amounts to €799.49. Table 3 reports details about all cost
items considered in the model associated with the two treat-
ment scenarios.
2.6 Sensitivity analysis
A probabilistic sensitivity analysis was conducted to assess
the uncertainty around the ICUR and the probability to be
cost-effective at a given cost per QALYs threshold.
In the probabilistic sensitivity analysis the transition
probability was modelled as beta-distributions, while the
costs were modelled as gamma-distributions, in accordance
with method of moments estimation [27].
2 Page 6 of 9 PharmacoEcon Ital Res Artic (2015) 17:2
Table 3 Cost and resource consumption
Propranolol (Hemangiol) Corticosteroids (Prednisolone-Deltacortene)
Pharmaceutical therapy costs
Dosage 1° week at 1.00 mg/kg/day 3 courses of 20 days each at 1,2mg/Kg/die +
gastro protector (Ranitidina) at 7.50 mg/kg/day2° week at 2.00 mg/kg/day
5.5 months at 3.00 mg/kg/day
Length of therapy 6 months 3 courses of 20 days
Costs* €1,510.79 €18.88
Hospitalization costs for the first administration of the drug
DRG coded DRG 284 “Minor skin disorders without
complications”




Type of visit Dermatological visit—code 89.7 General + Dermatological visit—code 89.7
Tariff €20.66 €20.66
Number of visits 8** 12
Costs €165.28 €247.92
Adverse events costs €153.00 €799.49
Ulceration events costs
DRG coded DRG 270 “Other skin procedure without complications”
Tariff €1,099.00
Type of visit Dermatological visit—code 89.7
Tariff €20.66
Number of visits 4
Costs €2,280.64
Surgical resection costs
DRG coded DRG 120 “Other acts on cardiovascular system”
Tariff €1,898.00
Laser therapy costs
DRG coded DRG 270 “Other skin procedure without complications”
Tariff €1,099.00
Number of session 3
Costs €3,297.00
*The estimate of pharmaceutical therapy costs was performed taking into account a average body weight equal to 7.24 Kg
**The total number of visits is 8 to take into account of 2 outpatient visits to perform the titration of the dosage
3 Results
Total costs, including pharmaceutical and healthcare costs
(outpatient and inpatient costs), related to propranolol treat-
ment were greater than total costs related to corticosteroids
treatment: €2,399.32 versus €1,859.68. This major re-
sources consumption was due to price difference between
the propranolol drug and corticosteroids (€180.50 versus
€1.04) and due to dosage and duration of the pharmaceuti-
cal therapies, 3 mg/Kg/day for 6 months for propranolol and
1.20 mg/Kg day for 3 courses of 20 days for corticosteroids.
The economic analysis showed that healthcare costs as-
sociated with propranolol were lower than costs associated
with corticosteroids (€994.29 versus €1,842.12, respec-
tively) (Table 4). However, some Hospitals may use a dif-
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Table 4 Summary of the final results*
Propranolol Corticosteroids
Base case p 2,5 p 97,5 Base case p 2,5 p 97,5
Pharmaceutical costs €1,405.03 €1,350.23 €1,453.47 €17.56 €16.88 €18.14
Healthcare costs €994.29 €709.01 €1,320.26 €1,842.12 €1,432.84 €2,082.19
Total costs €2,399.32 €2,059.24 €2,773.73 €1,859.68 €1,449.72 €2,100.33
Total QALYs 19.11 18.80 19.47 18.95 18.60 19.33
Base case p 2,5 p 97,5
ICUR €3,372.75/QALY €3,047.60/QALY €4.810.00/QALY
*The results were based on 30 year lifetime and 3% of discount rate for both costs and benefits
Fig. 2 Cost-effectiveness plan
(PSA)
ferent setting for the first administration for corticosteroids
(such as outpatient setting instead of day hospital), with a
consequently possible reduction of the costs of the treat-
ment.
Nevertheless, not taking into account the hospitalization
for the first administration of the drug that is common for the
two scenarios, a greater number of inpatient admissions and
outpatient visits was associated with the patients treated with
corticosteroids. Effectively the adoption of corticosteroids
in the treatment of proliferating IH implies a more inten-
sive follow-up plan with an additional outpatient visit (code
89.7-outpatient visit) compared to propranolol, and a major
numbers of hospitalizations to manage adverse events and
occurrence of ulceration.
The cumulative QALYs associated with propranolol oral
solution were equal to 19.11, while the cumulative QALYs
associated with corticosteroids were equal to 18.95.
The incremental costs related to the adoption of propra-
nolol oral solution in the treatment of proliferating IH were
equal to €539.64, while the incremental QALYS amounted
to 0.16, corresponding to an ICUR of €3,372.75 per QALY
gained.
The probabilistic sensitivity analysis demonstrated that
the model is robust and accurate to the variation of the in-
puts, as showed on the cost-effectiveness plan and on ac-
ceptability curve in Figs. 2 and 3. The results suggested that
94.60% of the 1,000 iterations fell within a €30,000 cost-
effectiveness threshold considered acceptable for a marginal
unit of effectiveness.
Table 4 resumes the final results of the economic evalua-
tion including the PSA results.
4 Discussion
IH is the most common vascular tumour of childhood that
develops due to abnormal changes in angiogenesis [7]. For
long time the therapy with corticosteroids was considered
as the first line treatment, even if their use was off-label
and only limited clinical evidence was available, until 2008,
when the publication by Léauté Labrèze et al. showed the ef-
ficacy of propranolol in patients affected by IH [14, 16]. Fol-
lowing this discovery several publications, including meta-
analyses and randomized clinical trials, have confirmed the
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Fig. 3 Acceptability curve
efficacy of propranolol in patients with IH and have demon-
strated that is a more effective and better tolerated treat-
ment than corticosteroids, with faster onset of action [1].
The scientific community has acknowledged the treatment
with propranolol as the best treatment available for the res-
olution of infantile haemangiomas [4].
In order to cover these unmet needs, an oral formula-
tion with propranolol, specifically for use in infants, was
developed in compliance with the formulation guidelines
for paediatric drugs and a full clinical development comply-
ing with a Paediatric Investigation Plan (PIP) has been con-
ducted, leading to a Paediatric Use Marketing Authorization
(PUMA) granted by EMA [17].
No economic analysis of propranolol in the treatment of
IH has previously been reported. Therefore, the authors con-
sidered it significant to carry out this study, as first economic
evaluation of treatment with propranolol in form of a regis-
tered medicinal product, establishing the economic value of
this therapy, in addition to evidence of safety and efficacy.
In particular the results obtained from the model showed
that implementing propranolol oral solutions in the treat-
ment of proliferating IH requiring systemic treatment can
significantly increase rate of resolution of the lesions on the
long term. Even if implementing propranolol implies addi-
tional cost for the introduction of the therapeutic treatment,
this therapy can be considered cost-effective from the Italian
National Health Service perspective, even though in Italy a
cost-effectiveness threshold is not clearly stated by institu-
tional body. However, in literature we can find, a range of
values of cost-effectiveness ratio variable from €17,907 per
QALY gained [28] to €25,000–€40,000 per QALY gained
[18]. Moreover, a threshold around €30,000/QALY is com-
monly accepted and applied in other health economic eval-
uations [29, 30].
Corticosteroids were included as comparator in this anal-
ysis because they were considered as standard of care in
some clinical settings, until discovery of propranolol phar-
macological effect in IH. Moreover they are only registered
for treatment of severe forms of hemangiomas in infants in
two countries in Europe (France and Germany). The most
part of publications use corticosteroids, considered as stan-
dard of care, as comparator versus propranolol such as the
recent randomized clinical trial of Bauman et al. that com-
pares the safety profile of oral propranolol and oral pred-
nisolone in the treatment of IH published in 2014 [3].
These results can be considered robust and accurate al-
though they come from a Markov model that is a simulation
and a simplification of real world. For this reason some as-
sumptions can be necessary that may influence the final re-
sults. In this regard some limitations can be identified in the
model.
The first is related to the absence of head-to-head data for
a direct comparison propranolol versus corticosteroids. In-
deed, the data for propranolol efficacy were extracted from
the MA holder’s pivotal trial, while data for corticosteroid
efficacy were based on a meta-analysis of observational
studies by Izadpanah expressed in terms of relative efficacy
respect efficacy of propranolol.
Another limitation of the study is represented by the es-
timate of utility for the patients affected by IH, using atopic
dermatitis as a proxy for IH. This kind of choice was made
due to lack of published studies investigating the utility val-
ues in order to estimate the quality of life. Even if the use
of atopic dermatitis as proxy is an assumption that poten-
tially influences the final results, this choice was validated
by a Focus Group composed by five Clinicians experts in
the treatment of IH, representatives of five Italian Regions
and two Pharmacoeconomists that considered it appropriate
since atopic dermatitis is a pathology with many similarities
to the Infantile Hemangioma.
Indeed the atopic dermatitis, especially in its more se-
vere form, causes strong itching and soreness that are source
of sleeplessness and can subsequently lead to tiredness and
mood changes, impacting significantly in quality of life like
IH [31]. Moreover the data regarding the utility used in the
economic evaluation are completely referred to Italian con-
text [24].
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5 Conclusion
The present finding suggests that the implementation of pro-
pranolol oral solution (in the treatment of IH requiring a
systemic therapy) results to be a cost-effective therapy com-
pared with corticosteroids from the Italian National Health
Service perspective.
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